TiGenix is a late-stage biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. TiGenix is developing a portfolio of products that address specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction affecting the mobility and functioning of patients. Western societies are characterised by ageing populations that place an increasing emphasis on high quality of life and life-long mobility, and, as such, cartilage problems represent a large and growing unmet medical need. Current therapies do not provide satisfying, long-term durable repair and TiGenix therefore believes there is a need for more effective treatments for cartilage damage.

ChondroCelect^®, the company’s lead product for cartilage regeneration in the knee, is the first cell-based product that successfully completed the entire development track from research, over clinical development to central European registration as a medicinal product. On October 5, 2009 ChondroCelect^® received European marketing authorisation as the first approved Advanced Therapy Medicinal Product (ATMP).

The company’s second product, Chondromimetic™, is an off-the-shelf, resorbable implant for the minimally invasive repair of small osteochondral defects. The product has received CE-Mark approval and is close to entering the European market. Chondromimetic forms an excellent fit with ChondroCelect, since both products target the same customer base in complementary indications.

TiGenix’ headquarters are situated at the Researchpark of Haasrode (Belgium). The company has recently established a presence in Cambridge, UK. Furthermore, TiGenix has established  production facilities in Leuven (Belgium) and in Memphis (TN, USA). The company is currently building a third production facility in Sittard-Geleen (The Netherlands).